Imidafenacin, An Orally Active Muscarinic Receptor Antagonist, Improves Pulmonary Function In Patients With Chronic Obstructive Pulmonary Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled 3×3 Crossover Phase II Trial

Imidafenacin, An Orally Active Muscarinic Receptor Antagonist, Improves Pulmonary Function In Patients With Chronic Obstructive Pulmonary Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled 3×3 Crossover Phase II Trial

Kentaro Machida,1,* Tomotaka Kawayama,2,* Masaharu Kinoshita,3,* Masakazu Ichinose,4 Tohru Tsuda,5 Shohei Takata,6 Hiroshi Koto,7 Makoto Yoshida,8 Yoshinori Ashihara,9 Masaru Kawashima,10 Hideaki Suna,10 Hiromasa Inoue1 1Department of Pulmonary Medicine, Graduate School of Medical and Dental Science...

Full description

Bibliographic Details
Main Authors: Machida K, Kawayama T, Kinoshita M, Ichinose M, Tsuda T, Takata S, Koto H, Yoshida M, Ashihara Y, Kawashima M, Suna H, Inoue H
Format: Article
Language:English
Published: Dove Medical Press 2019-09-01
Series:International Journal of COPD
Subjects:
anti-cholinergic
bronchodilator
imidafenacin
lung function
COPD
Online Access:https://www.dovepress.com/imidafenacin-an-orally-active-muscarinic-receptor-antagonist-improves--peer-reviewed-article-COPD

Internet

https://www.dovepress.com/imidafenacin-an-orally-active-muscarinic-receptor-antagonist-improves--peer-reviewed-article-COPD

Similar Items